HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer

Molecular alterations that contribute to long-term (LT) and short-term (ST) survival in ovarian high-grade serous carcinoma (HGSC) may be used as precision medicine biomarkers. DNA promoter methylation is an early event in tumorigenesis, which can be detected in blood and urine, making it a feasible companion biomarker to somatic mutations for early detection and targeted treatment workflows. We compared the methylation profile in 12 HGSC tissue samples to 30 fallopian tube epithelium samples, using the Infinium Human Methylation 450K Array. We also used 450K methylation arrays to compare methylation among HGSCs long-term survivors (more than 5 years) and short-term survivors (less than 3 years). We verified the array results using bisulfite sequencing and methylation-specific PCR (qMSP). in another cohort of HGSC patient samples (n = 35). Immunoblot and clonogenic assays after pharmacologic unmasking show that HIST1H2BB and MAGI2 promoter methylation downregulates mRNA expression levels in ovarian cancer cells. We then used qMSP in paired tissue, ascites, plasma/serum, vaginal swabs, and urine from a third cohort of patients with HGSC cancer (n = 85) to test the clinical potential of HIST1H2BB and MAGI2 in precision medicine workflows. We also performed next-generation exome sequencing of 50 frequently mutated in human cancer genes, using the Ion AmpliSeqCancer Hotspot Panel, to show that the somatic mutation profile found in tissue and plasma can be quantified in paired urine samples from patients with HGSC. Our results suggest that HIST1H2BB and MAGI2 have growth-suppressing roles and can be used as HGSC precision medicine biomarkers.

[1]  V. Beral,et al.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer , 2015, Nature Reviews Cancer.

[2]  N. Hulo,et al.  Monoubiquitination of Histone H2B Blocks Eviction of Histone Variant H2A.Z from Inducible Enhancers. , 2016, Molecular cell.

[3]  E. Schuuring,et al.  Genome-wide promoter analysis uncovers portions of the cancer methylome. , 2008, Cancer research.

[4]  A. Lytwyn,et al.  Frequency of Serous Tubal Intraepithelial Carcinoma in Various Gynecologic Malignancies: A Study of 300 Consecutive Cases , 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[5]  P. Laird.  Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[6]  Lee T. Sam,et al.  Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. , 2011, Genome research.

[7]  A. El-Osta,et al.  Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing , 2005, Nature Genetics.

[8]  K. Yamashita,et al.  DNA diagnosis of peritoneal fluid cytology test by CDO1 promoter DNA hypermethylation in gastric cancer , 2017, Gastric Cancer.

[9]  B. Trock,et al.  Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes , 2016, Cancer Prevention Research.

[10]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.

[11]  P. Thota,et al.  Use of a positional therapy device significantly improves nocturnal gastroesophageal reflux symptoms. , 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[12]  Zu-Wen Sun,et al.  Histone H 2 B ubiquitination and beyond Regulation of nucleosome stability , chromatin dynamics and the trans-histone H 3 methylation , 2010 .

[13]  G. Scambia,et al.  Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus , 2018, Oncotarget.

[14]  D. Patel,et al.  DNA methylation pathways and their crosstalk with histone methylation , 2015, Nature Reviews Molecular Cell Biology.

[15]  Sam Angiuoli,et al.  Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.

[16]  T. Sellers,et al.  Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. , 2013, Journal of the National Cancer Institute.

[17]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[18]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[19]  G. Debelouchina,et al.  Functional crosstalk between histone H2B ubiquitylation and H2A modifications and variants , 2018, Nature Communications.

[20]  Y. Sakamoto,et al.  Monitoring sputum culture in resected esophageal cancer patients with preoperative treatment. , 2017, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[21]  Cheng-Chang Chang,et al.  The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings , 2017, Journal of gynecologic oncology.

[22]  C. Sawyers,et al.  MAGI-2 scaffold protein is critical for kidney barrier function , 2014, Proceedings of the National Academy of Sciences.

[23]  Kisha I Coa,et al.  Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices. , 2018, Gynecologic oncology.

[24]  M. Sherman,et al.  Population Frequency of Serous Tubal Intraepithelial Carcinoma (STIC) in Clinical Practice Using SEE-Fim Protocol. , 2018, JNCI cancer spectrum.

[25]  D. Frishman,et al.  Identification of novel hereditary cancer genes by whole exome sequencing. , 2015, Cancer letters.

[26]  Mingwei Yu,et al.  Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis , 2017, Clinical and translational gastroenterology.

[27]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[28]  M. Hidalgo,et al.  Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  M. Esteller,et al.  DNA methylation profiling in the clinic: applications and challenges , 2012, Nature Reviews Genetics.

[30]  Matthew E. Ritchie,et al.  illuminaio: An open source IDAT parsing tool for Illumina microarrays , 2013, F1000Research.

[31]  P. Laird,et al.  Low-level processing of Illumina Infinium DNA Methylation BeadArrays , 2013, Nucleic acids research.

[32]  R. Bast,et al.  Cell Origins of High-Grade Serous Ovarian Cancer , 2018, Cancers.

[33]  Russell Vang,et al.  Fallopian tube precursors of ovarian low‐ and high‐grade serous neoplasms , 2013, Histopathology.

[34]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[35]  Bert Vogelstein,et al.  DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .

[36]  H. Shahrokh,et al.  Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer , 2014, Molecular Biology Reports.

[37]  L. Cope,et al.  Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma , 2017, Nature Communications.

[38]  Yi-Chun Chen,et al.  Histone H2B C-Terminal Helix Mediates trans-Histone H3K4 Methylation Independent of H2B Ubiquitination , 2010, Molecular and Cellular Biology.

[39]  Zu-Wen Sun,et al.  Histone H2B ubiquitination and beyond , 2010, Epigenetics.

[40]  M. Adelson,et al.  Simultaneous detection of herpes simplex virus types 1 and 2 by real-time PCR and Pyrosequencing. , 2005, Journal of Clinical Virology.

[41]  Todd R. Golub,et al.  Abstract 1028: Patient-derived xenografts undergo mouse-specific tumor evolution , 2018, Tumor Biology.

[42]  A. Oza,et al.  Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors , 2018, Genome Medicine.

[43]  Wulfran Cacheux,et al.  Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response. , 2016, Critical reviews in oncology/hematology.

[44]  K. Asanuma,et al.  MAGI-2 is critical for the formation and maintenance of the glomerular filtration barrier in mouse kidney. , 2014, The American journal of pathology.

[45]  K. Yamashita,et al.  Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma. , 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[46]  Y. Kitagishi,et al.  Roles of PI3K/AKT/PTEN Pathway as a Target for Pharmaceutical Therapy , 2013, The open medicinal chemistry journal.

[47]  K. Yamashita,et al.  Comprehensive molecular exploration identified promoter DNA methylation of the CRBP1 gene as a determinant of radiation sensitivity in rectal cancer , 2017, British Journal of Cancer.

[48]  Rafael A. Irizarry,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[49]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[50]  T. Lenstra,et al.  Dot1 promotes H2B ubiquitination by a methyltransferase-independent mechanism , 2018, Nucleic acids research.

[51]  K. Yamashita,et al.  Analysis of DNA Methylation Status in Bodily Fluids for Early Detection of Cancer , 2017, International journal of molecular sciences.

[52]  Xiumei Cai,et al.  MAGI-2 Inhibits cell migration and proliferation via PTEN in human hepatocarcinoma cells. , 2007, Archives of biochemistry and biophysics.

[53]  E. Berns,et al.  Epithelial Ovarian Cancer: Rationale for Changing the One-Fits-All Standard Treatment Regimen to Subtype-Specific Treatment , 2014, International Journal of Gynecologic Cancer.

[54]  Y. Dong,et al.  Bre1-dependent H2B ubiquitination promotes homologous recombination by stimulating histone eviction at DNA breaks , 2018, Nucleic acids research.

[55]  Cheng-Chang Chang,et al.  Methylomics analysis identifies epigenetically silenced genes and implies an activation of β‐catenin signaling in cervical cancer , 2014, International journal of cancer.